Daxor Corporation

About Daxor Corporation

Daxor Corporation (NASDAQ: DXR) is a global leader in blood volume analysis, addressing healthcare's critical issue of imprecise blood volume measurement. With over 50 years of innovation, Daxor offers FDA-cleared Blood Volume Analysis (BVA) diagnostics that provide real-time, precise data to empower clinicians in making individualized treatment decisions. Their mission is to achieve optimal blood volume for all, improving patient outcomes and delivering efficiencies in value-based healthcare.

Products & Services

Daxor BVA™ Analyzer:A next-generation, FDA-cleared, patented system for blood volume analysis, offering speed, ease of use, and portability for hospital and ambulatory settings. It provides lab-quality data for earlier, data-driven interventions.

BVA-100:A predicate device for blood volume measurement with over 75,000 tests conducted, used as a foundation for the new BVA™ Analyzer. It assists in diagnosing and managing patient conditions.

ezBVA Lab Services:Laboratory services supporting blood volume analysis for healthcare professionals.

Specialties

Blood Volume Analysis (BVA) Heart Failure Management Critical Care Sepsis Treatment Surgical Blood Loss Management ARDS (Acute Respiratory Distress Syndrome) Treatment Syncope Diagnosis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9000000 MR: - FA: $9 million FAN: 9000000	D: 2026-01-23 FD: 2026-01-23	1 investors
2	RT: SBIR Matching Fund T: - FT: SBIR Matching Fund	A: 300000 MR: - FA: $300K FAN: 300000	D: 2024-09-05 FD: 2024-09-05	1 investors
3	RT: Secondary Offering T: - FT: Secondary Offering	A: 529805 MR: - FA: 529805.25 USD FAN: 529805	D: 2023-06-22 FD: 2023-06-22	1 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 4000000 MR: - FA: 4.0 million FAN: 4000000	D: 2023-05-25 FD: 2023-05-25	2 investors
5	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 4000000 MR: - FA: $4.0 million FAN: 4000000	D: 2023-05-22 FD: 2023-05-22	2 investors

Registered Direct Offering Latest

2026-01-23

$9.0M

1 investor (Pro only)

SBIR Matching Fund 2024-09-05

$300K

Secondary Offering 2023-06-22

$530K

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Feldschuh

President and CEO

J

Jeff Bezos

M

Michael R. Feldschuh

Director

H

Henry D. Cremisi

Medical Director (Renal)

J

Jonathan Feldschuh

Chief Scientific Officer

E

Edward S. Feuer

Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News